General description
Agrin C-terminal human recombinant is expressed in human HEK 293 cells as a glycoprotein with a calculated molecular mass of 87 kDa (amino acids Ala1260-Pro2045, with an N-terminal His tag). The DTT-reduced protein migrates as a ∼100 kDa polypeptide on SDS-PAGE due to glycosylation. This protein is manufactured in human cells, with no serum. The human cells expression system allows human-like glycosylation and folding, and often supports higher bioactivity of the protein.
Biochem/physiol Actions
Agrin is a large extracellular heparan sulfate proteoglycan that is involved in the formation of the neuromuscular junction.
Agrin triggers the aggregation of acetylcholine receptors via the muscle-specific kinase (MuSK) and the low-density lipoprotein receptor-related protein 4 (Lrp4) receptor complex.
Agrin is required for the full regenerative capacity of neonatal mouse hearts.
Recombinant agrin has been shown in vitro to promote cardiomyocyte proliferation, as studied in mouse-induced and human-induced pluripotent stem cells. Recombinant agrin has been shown in vivo to promote cardiac regeneration, after induction of myocardial infarction in adult mice.
| recombinant | expressed in HEK 293 cells |
| assay | ≥95% (SDS-PAGE) |
| form | lyophilized powder |
| potency | attachment assay, measured by the ability of the immobilized agrin to support the adhesion of PC12 cells |
| technique(s) | cell culture | mammalian: suitable |
| suitability | endotoxin tested |
| shipped in | ambient |
| storage temp. | −20°C |
